Fareed Kannout, MD
Internal Medicine · Fort Smith, ARNPI 1144242892
Payments from drug & device makers
Across 138 payments — averaging $16.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$778
- AstraZeneca$562
- Amgen$270
- GSK$127
- Pfizer$83
- Bayer$64
- plus $378 from 12 others
What the payments were for
- Food & beverage$2,257100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 45 | $778 |
| AstraZeneca | 33 | $562 |
| Amgen(2 entities) | 18 | $270 |
| GSK | 9 | $127 |
| Pfizer | 5 | $83 |
| Bayer | 4 | $64 |
| Abbott | 3 | $63 |
| Johnson & Johnson | 4 | $60 |
| Exact Sciences | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $35 |
| Lilly USA, LLC | 2 | $33 |
| Boehringer Ingelheim | 2 | $32 |
| Biohaven Pharmaceuticals, Inc. | 2 | $25 |
| Inari Medical, Inc. | 1 | $21 |
| Eisai Inc. | 1 | $15 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Genentech USA, Inc. | 1 | $13 |
| Zyla Life Sciences, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$250
How this compares
$2,262 in reported general payments places this provider in the 80th percentile of 614 internal medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 92 | $118,440 |
| EliquisApixaban | 112 | $111,789 |
| JardianceEmpagliflozin | 104 | $108,435 |
| JanuviaSitagliptin Phosphate | 53 | $57,510 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $41,022 |
| LinzessLinaclotide | 30 | $29,454 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 42 | $28,449 |
| TrulicityDulaglutide | 13 | $27,529 |
| XareltoRivaroxaban | 29 | $23,914 |
| EntrestoSacubitril/Valsartan | 25 | $22,641 |
| MounjaroTirzepatide | 13 | $15,634 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 111 | $14,712 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $9,693 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 37 | $9,614 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 43 | $7,644 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $83 | $111,789112 claims |
| Boehringer IngelheimJardiance | $32 | $108,435104 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $127 | $44,85473 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $33 | $43,16326 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $562 | $38,14174 claims |
| AbbVieLinzess, Synthroid | $778 | $33,60172 claims |
| Johnson & JohnsonXarelto | $60 | $23,91429 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 614 internal medicine providers in Arkansas.
Other internal medicine in Fort Smith
- Tyree SealsFort Smith$14K
- Hubert LandersFort Smith$7K
- Brent ReevesFort Smith$6K
- Beena SyedFort Smith$6K
- Kendall WagnerFort Smith$6K
- Sumer PhillipsFort Smith$6K
- Becky YarboroughFort Smith$6K
- Priyantha WijewardaneLittle Rock$43.6M
- Joseph RoseLittle Rock$1.1M
- David JohnsonSearcy$630K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.